About QuidelOrtho
QuidelOrtho is a company based in San Diego (United States) founded in 1937. QuidelOrtho has raised $69.05 million across 15 funding rounds from investors including HHS, European Union and Algert Global. The company has 6,600 employees as of December 31, 2024. QuidelOrtho offers products and services including QuickVue COVID-19 Test, Sofia Platform, and Solana Molecular Testing Platform.
- Headquarter San Diego, United States
- Employees 6600 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Quidelortho Corporation
-
Annual Revenue
$2.73 B (USD)-1.98as on Dec 31, 2025
-
Net Profit
-$1.13 B (USD)44.84as on Dec 31, 2025
-
EBITDA
$496.8 M (USD)-1.04as on Dec 31, 2025
-
Total Equity Funding
$69.05 M (USD)
in 15 rounds
-
Latest Funding Round
$20.69 K (USD), Grant
Dec 30, 2021
-
Investors
HHS
& 2 more
-
Employee Count
6600
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of QuidelOrtho
QuidelOrtho is a publicly listed company on the NASDAQ with ticker symbol QDEL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of QuidelOrtho
QuidelOrtho offers a comprehensive portfolio of products and services, including QuickVue COVID-19 Test, Sofia Platform, and Solana Molecular Testing Platform.
Fast lateral-flow test for detecting COVID-19 at home
Benchtop system for rapid diagnostic testing
Platform for faster molecular assays in labs
People of QuidelOrtho
Unlock access to complete
Software Development Team
119 people
Leadership Team
62 people
Sales and Marketing
56 people
Senior Team
56 people
Finance and Accounting
44 people
Human Resources and Administration
25 people
Product Management Team
25 people
Data Analysis and Operations Team
18 people
Unlock access to complete
Funding Insights of QuidelOrtho
QuidelOrtho has successfully raised a total of $69.05M across 15 strategic funding rounds. The most recent funding activity was a Grant round of $20.69 thousand completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in QuidelOrtho
QuidelOrtho has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, European Union and Algert Global.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Systematic equity investment firm managing capital for institutional investors globally.
|
Locked | Locked | Locked |
Investor details for QuidelOrtho
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by QuidelOrtho
Investment portfolio details for QuidelOrtho
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - QuidelOrtho
Detailed financials for QuidelOrtho
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Quidelortho Comparisons
Peer comparison for QuidelOrtho
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of QuidelOrtho
Detailed competitors of QuidelOrtho
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Quidelortho
Complete news archive for QuidelOrtho
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about QuidelOrtho
QuidelOrtho was founded in 1937 and raised its 1st funding round 71 years after it was founded.
QuidelOrtho is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Douglas Bryant is the current CEO of QuidelOrtho.
QuidelOrtho is a funded company, having raised a total of $69.05M across 15 funding rounds to date.
As of Dec 31, 2024, the latest employee count at QuidelOrtho is 6,600.
Annual revenue of QuidelOrtho is $2.73B as on Dec 31, 2025.
QuidelOrtho, backed by 73950786.456085 from European Union, HHS, Algert Global, focuses on providing healthcare solutions, and diversified diagnostics. Provider of healthcare information services. Driving innovation, growth, and excellence in its industry sectors. It continues to evolve, meeting industry challenges with strategic approaches.
QuidelOrtho offers QuickVue COVID-19 Test, Sofia Platform, and Solana Molecular Testing Platform.
Yes, QuidelOrtho is publicly traded on NASDAQ under the ticker symbol QDEL.
QuidelOrtho has 3 investors. Key investors include HHS, European Union, and Algert Global.
The ticker symbol of QuidelOrtho is QDEL on NASDAQ.